sermorelin body composition: Frequently asked questions

Check dietary protein intake. IGF-1 elevation alone doesn't build muscle without substrate availability. Studies that don't control for protein intake (minimum 1.6g/kg/day) show IGF-1 increases without corresponding lean mass gains. The second possibility: insufficient mechanical stimulus. Sermorelin amplifies the anabolic response to resistance training, but in sedentary populations, the baseline stimulus is near zero. A 2018 study in Aging Cell found that sermorelin plus resistance training produced 3× the lean mass gain of sermorelin alone in adults over 60.

Verify peptide potency first. Request HPLC analysis of the batch used. Studies using sermorelin without third-party purity verification frequently report null results because the administered peptide was degraded, incorrectly synthesized, or stored improperly. If peptide integrity is confirmed, check baseline IGF-1 levels in participants. Individuals with IGF-1 above 200ng/mL at baseline show minimal response to sermorelin because their endogenous GH secretion is already sufficient. The mechanism only works when there's a deficiency to correct.

This is common and expected. A 2kg lean mass gain distributed across the entire body is not perceptible in the mirror or on a standard scale. It requires DEXA to detect. Sermorelin help body composition research is measured instrumentally, not subjectively. Participants often report no change in appearance or strength despite statistically significant DEXA-measured improvements, which is why objective measurement endpoints are mandatory in study design.

Unreconstituted lyophilized sermorelin powder tolerates brief temperature excursions (up to 25°C for 48 hours) with minimal potency loss. Once reconstituted, however, the peptide solution degrades rapidly above 8°C. 12 hours at room temperature reduces bioavailability by approximately 30%, and 24 hours renders it nearly inactive. If a reconstituted vial was left out overnight, discard it and reconstitute a fresh vial rather than risk injecting denatured peptide. There's no visual indicator of degradation. The solution will appear clear and normal even after complete denaturation.

Discontinuing sermorelin without a transition strategy typically results in 60–70% reversion to pre-treatment body composition within 6–9 months as endogenous GH secretion returns to baseline. Maintenance options include: reducing to a twice-weekly dosing schedule (200 mcg per injection) to sustain partial GH elevation, transitioning to lifestyle interventions that support endogenous GH production (high-intensity interval training, adequate sleep, reduced refined carbohydrate intake), or periodic cycling (12 weeks on, 4 weeks off) to prevent receptor desensitization while maintaining partial composition benefits. Consult the prescribing physician before altering protocols.

Stacking sermorelin with CJC1295 Ipamorelin can amplify GH release by targeting multiple pathways simultaneously. Sermorelin stimulates release, ipamorelin amplifies pulse amplitude, and CJC-1295 (a GHRH analog with extended half-life) prolongs GH elevation. This combination typically produces faster IGF-1 elevation and earlier visible results, with some users reporting detectable changes by week 6 instead of week 8–12. The trade-off is increased receptor downregulation risk and higher cost.

Get blood work to measure IGF-1 levels. If IGF-1 hasn't risen from baseline despite 12 weeks of nightly sermorelin at 200–500mcg, the issue is either inadequate dosing, degraded peptide quality, or poor pituitary responsiveness. Some individuals. Particularly those over 60 or with long-term exogenous GH use history. Have blunted GHRH receptor sensitivity. If IGF-1 is elevated but body composition hasn't changed, the problem is downstream: insufficient training stimulus, inadequate protein intake, or undiagnosed metabolic dysfunction (hypothyroidism, insulin resistance).

Lean mass gained through sermorelin is real tissue, not water retention or glycogen. It doesn't vanish immediately when you stop. However, without the elevated IGF-1 environment, muscle protein synthesis returns to baseline levels, and any gains not supported by continued training stimulus will gradually erode over 3–6 months. Fat loss is more durable. Metabolic improvements and reduced visceral adiposity tend to persist longer, especially if dietary habits remain consistent.

First, verify dosage and administration timing. Sermorelin must be injected 30–60 minutes before sleep to align with the body's natural nocturnal GH surge. Second, request baseline and follow-up IGF-1 testing: if IGF-1 levels haven't increased by at least 40 ng/mL after eight weeks, either the dose is subtherapeutic or the peptide has degraded due to improper storage. Third, confirm you're measuring composition change with DEXA or clinical BIA, not scale weight. Simultaneous fat loss and muscle gain often produce minimal weight change despite significant recomposition.

Non-response occurs in approximately 15–20% of individuals due to pituitary hyporesponsiveness or somatopause (age-related decline in GH secretion capacity). First, verify peptide integrity. Improper storage or reconstitution technique can render sermorelin inactive without visible degradation. If storage was correct, increase dose to 400–500mcg nightly and retest IGF-1 at week 12. If IGF-1 remains below 200ng/ml, sermorelin monotherapy is unlikely to produce meaningful body composition changes. Consider switching to a GH secretagogue with a different mechanism (e.g., ipamorelin or MK 677, which acts as a ghrelin mimetic rather than a GHRH analogue).

Discard the vial immediately. Peptides are temperature-sensitive proteins. Any excursion above 8°C for more than 2 hours causes irreversible denaturation. Even if the solution appears clear and unchanged, the peptide structure has degraded and will not bind effectively to GHRH receptors. Using degraded sermorelin isn't dangerous, but it's therapeutically useless. You're injecting inactive protein fragments. Refrigeration at 2–8°C is non-negotiable for reconstituted peptides.

Sermorelin's effects are not immediately perceptible. Unlike exogenous GH, which produces acute changes in water retention and glucose metabolism within 48 hours, sermorelin amplifies endogenous GH pulses gradually. IGF-1 elevation takes 2–4 weeks to reach steady state, and measurable body composition changes require 8–12 weeks. Absence of subjective effects during week one is normal and expected. The only early indicators are improved sleep depth (reported by 40–60% of users within 10–14 days) and faster recovery from resistance training. If IGF-1 levels remain unchanged after 4 weeks, the peptide may be degraded or the dose insufficient.